Erasca(ERAS) - 2025 Q4 - Annual Results

Exhibit 99.1 Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, ...